The Putative Melatonin Receptor Antagonist GR128107 is a Partial Agonist on Xenopus Laevis Melanophores

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 1999 Apr 16

PMID 10205014

Citations 3

Authors

M T Teh

D Sugden

Affiliations

Soon will be listed here.

Abstract

1. GR128107 (3-(1-acetyl-3-methyl-piperidine)-5-methoxyindole) has previously been reported to be a competitive melatonin receptor antagonist in blocking melatonin inhibition of [3H]-dopamine release from rabbit retina, a response mediated by the MT2 receptor subtype. 2. GR128107, like melatonin, induced a rapid (maximum response in 60-90 min) pigment aggregation in a clonal line of Xenopus laevis melanophores. GR128107 behaved as a partial agonist (pEC50 8.58+/-0.03, n=3) with an Emax of 0.83 (relative to melatonin, pEC50 10.09+/-0.03, n=3). 3. The concentration-response curve for pigment granule aggregation to both melatonin and GR128107 was displaced in a parallel, rightward manner by melatonin receptor antagonists with very similar potencies; estimated pKB RJ252 (against melatonin 4.60/against GR128107 4.54) < GR135533 (6.40/6.14) < Luzindole (6.45/6.49) < S20929 (6.58/6.65) < 4-P-PDOT (6.73/6.85). 4. Both melatonin- and GR128107-induced pigment granule aggregation was prevented by pretreatment of melanophores with pertussis toxin (10-1000 ng ml(-1)). 5. Prolonged pre-treatment of melanophores with melatonin desensitized the pigment aggregation response to GR128107. In desensitized cells, the maximal aggregation produced by GR128107 was only 0.27+/-0.01 (n=4) and the pEC50 was reduced (vehicle 8.57+/-0.12; melatonin pre-treated 7.84+/-0.09, n=4). The maximal response to melatonin in desensitized melanophores was unchanged but the pEC50 was reduced (vehicle 10.49+/-0.03; melatonin pre-treated 9.83+/-0.04, n=4). 6. These results demonstrate that GR128107 induces pigment granule aggregation in Xenopus melanophores by activating a cell membrane melatonin receptor coupled via a pertussis toxin-sensitive G-protein. 7. The partial agonist activity of GR128107 in melanophores may be apparent because of the very high density of melatonin receptors in these cells (Bmax 1223 fmol mg protein(-1)) compared to the low density of sites in rabbit retina (Bmax 3.1 fmol mg protein(-1)). This suggestion is supported by the finding that GR128107, like melatonin, acted as a full agonist and inhibited forskolin-stimulation of cyclic AMP accumulation in NIH-3T3 cells expressing a high density of human mt1 or MT2 receptors.

Citing Articles

Melatonin.

Pevet P Dialogues Clin Neurosci. 2011; 4(1):57-72.

PMID: 22034091 PMC: 3181670.

International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.

Dubocovich M, Delagrange P, Krause D, Sugden D, Cardinali D, Olcese J Pharmacol Rev. 2010; 62(3):343-80.

PMID: 20605968 PMC: 2964901. DOI: 10.1124/pr.110.002832.

An endogenous 5-HT(7) receptor mediates pigment granule dispersion in Xenopus laevis melanophores.

Teh M, Sugden D Br J Pharmacol. 2001; 132(8):1799-808.

PMID: 11309252 PMC: 1572726. DOI: 10.1038/sj.bjp.0703988.

References

Reppert S, Godson C, Mahle C, Weaver D, Slaugenhaupt S, Gusella J . Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci U S A. 1995; 92(19):8734-8. PMC: 41041. DOI: 10.1073/pnas.92.19.8734. View

Reiter R, Melchiorri D, Sewerynek E, Poeggeler B, Chuang J, Ortiz G . A review of the evidence supporting melatonin's role as an antioxidant. J Pineal Res. 1995; 18(1):1-11. DOI: 10.1111/j.1600-079x.1995.tb00133.x. View

Attenburrow M, Dowling B, Sargent P, Sharpley A, Cowen P . Melatonin phase advances circadian rhythm. Psychopharmacology (Berl). 1995; 121(4):503-5. DOI: 10.1007/BF02246501. View

McClintock T, Rising J, Lerner M . Melanophore pigment dispersion responses to agonists show two patterns of sensitivity to inhibitors of cAMP-dependent protein kinase and protein kinase C. J Cell Physiol. 1996; 167(1):1-7. DOI: 10.1002/(SICI)1097-4652(199604)167:1<1::AID-JCP1>3.0.CO;2-T. View

Mazzucchelli C, Pannacci M, Nonno R, Lucini V, Fraschini F, Stankov B . The melatonin receptor in the human brain: cloning experiments and distribution studies. Brain Res Mol Brain Res. 1996; 39(1-2):117-26. DOI: 10.1016/0169-328x(96)00017-4. View

Pickering H, Sword S, Vonhoff S, Jones R, Sugden D . Analogues of diverse structure are unable to differentiate native melatonin receptors in the chicken retina, sheep pars tuberalis and Xenopus melanophores. Br J Pharmacol. 1996; 119(2):379-87. PMC: 1915861. DOI: 10.1111/j.1476-5381.1996.tb15997.x. View

Pappolla M, Sos M, Omar R, Bick R, Reiter R, Efthimiopoulos S . Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci. 1997; 17(5):1683-90. PMC: 6573387. View

Dubocovich M, Masana M, Iacob S, Sauri D . Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol. 1997; 355(3):365-75. DOI: 10.1007/pl00004956. View

Geary G, Krause D, Duckles S . Melatonin directly constricts rat cerebral arteries through modulation of potassium channels. Am J Physiol. 1997; 273(3 Pt 2):H1530-6. DOI: 10.1152/ajpheart.1997.273.3.H1530. View

10.

Ting K, Dunn W, Davies D, Sugden D, Delagrange P, Guardiola-Lemaitre B . Studies on the vasoconstrictor action of melatonin and putative melatonin receptor ligands in the tail artery of juvenile Wistar rats. Br J Pharmacol. 1998; 122(7):1299-306. PMC: 1565073. DOI: 10.1038/sj.bjp.0701511. View

11.

Arendt J . Melatonin and the pineal gland: influence on mammalian seasonal and circadian physiology. Rev Reprod. 1998; 3(1):13-22. DOI: 10.1530/ror.0.0030013. View

12.

Sugden D, Pickering H, Teh M, Garratt P . Melatonin receptor pharmacology: toward subtype specificity. Biol Cell. 1998; 89(8):531-7. DOI: 10.1016/s0248-4900(98)80009-9. View

13.

Harper J, Brooker G . Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2'0 acetylation by acetic anhydride in aqueous solution. J Cyclic Nucleotide Res. 1975; 1(4):207-18. View

14.

Bradford M . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54. DOI: 10.1016/0003-2697(76)90527-3. View

15.

Holmes S, Sugden D . Effects of melatonin on sleep and neurochemistry in the rat. Br J Pharmacol. 1982; 76(1):95-101. PMC: 2068766. DOI: 10.1111/j.1476-5381.1982.tb09194.x. View

16.

Kenakin T, Ferris R . Effects of in vivo beta-adrenoceptor down-regulation on cardiac responses to prenalterol and pirbuterol. J Cardiovasc Pharmacol. 1983; 5(1):90-7. DOI: 10.1097/00005344-198301000-00014. View

17.

Kenakin T . The relative contribution of affinity and efficacy to agonist activity: organ selectivity of noradrenaline and oxymetazoline with reference to the classification of drug receptors. Br J Pharmacol. 1984; 81(1):131-41. PMC: 1986943. DOI: 10.1111/j.1476-5381.1984.tb10753.x. View

18.

Kenakin T . The classification of drugs and drug receptors in isolated tissues. Pharmacol Rev. 1984; 36(3):165-222. View

19.

Vanecek J, Sugden D, Weller J, Klein D . Atypical synergistic alpha 1- and beta-adrenergic regulation of adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate in rat pinealocytes. Endocrinology. 1985; 116(6):2167-73. DOI: 10.1210/endo-116-6-2167. View

20.

WHITE B, Sekura R, Rollag M . Pertussis toxin blocks melatonin-induced pigment aggregation in Xenopus dermal melanophores. J Comp Physiol B. 1987; 157(2):153-9. DOI: 10.1007/BF00692359. View